Ascites| A Drug Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Aug 2, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat ascites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005720/en/
Technavio has published a new report on the drug development pipeline for ascites, including a detailed study of the pipeline molecules (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Ascites: Market overview
Ascites refers to the accumulation of fluid in the peritoneal cavity. The organs of the abdomen are situated in a sac-like structure called the peritoneum. Generally, the amount of fluid in the peritoneal activity is very less. This can vary by 20 ml or less than an ounce in woman depending on the menstrual cycle. A variety of diseases can cause fluid accumulation. The direct leakage of fluid is an after-effect of cancer that spreads to the peritoneum. In addition, there are other illnesses that cause excess accumulation of water and sodium in the body, which eventually leads to leakage of fluid into the peritoneal cavity.
According to a senior market research analyst at Technavio, “The other causes of ascites include liver disease, the inability of organs to produce enough protein to retain fluid in the bloodstream and the obstruction of flow through the scarred cirrhotic liver. The proteins prevent the leakage of water molecules from capillary blood vessels into surrounding tissues. The liver’s ability to produce proteins is decreased by the progression of liver disease. This results in a lack of protein in the body. Water leaks into the surrounding tissues, thus decreasing oncotic pressure.”
Ascites: Segmentation analysis
This pipeline analysis report segments the ascites market based on therapies employed (monotherapy), RoA (intravenous and intraperitoneal), therapeutic modality (peptide, monoclonal antibody, fusion protein, recombinant protein, and bispecific antibody), targets (CLEC10A receptor, TRAIL receptor, tubulin, AVPR1 and AVPR2, vasopressin type 2 receptor, B7-H3 (CD276), and EpCAM and CD3 ), MoA (CLEC10A receptor agonist, TRAIL receptor agonist, tubulin inhibitor, AVPR1 and AVPR2 agonist, immunostimulator, vasopressin type 2 receptor antagonist, B7-H3 (CD276) inhibitor, and EpCAM and CD3 inhibitor), geographical segmentation (US and Australia) and recruitment status (recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 36% of the molecules that are being investigated for the treatment of ascites are peptide, which is a short chain of amino acids
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005720/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL OTHER HEALTH OTHER SCIENCE SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/02/2018 01:17 PM/DISC: 08/02/2018 01:17 PM